Dravet Syndrome Foundation (DSF) is pleased to be funding five new research grants, including two that have been co-funded with JAM for Dravet. DSF is proud to be the largest non-governmental funder ...

Stoke Therapeutics plans to provide an update regarding a global, randomized phase 3 registrational study by the end of the year. The Food and Drug Administration (FDA) has granted Breakthrough ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...

– Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over available therapies – – Update on the company’s plans for a global, ...

In a combined analysis of the early U.S.-based MONARCH and U.K.-based ADMIRAL studies, the drug showed mild or moderate adverse effects and no significant safety problems, reported Linda Laux, MD, of ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in ...